Rationale and design of a multicenter, randomized phase II trial of durvalumab with or without multitarget tyrosine kinase inhibitor as maintenance treatment in extensive-stage small-cell lung cancer patients (DURABLE study),Clinical Respiratory Journal

当前位置： X-MOL 学术 › Clin. Respir. J. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Rationale and design of a multicenter, randomized phase II trial of durvalumab with or without multitarget tyrosine kinase inhibitor as maintenance treatment in extensive-stage small-cell lung cancer patients (DURABLE study)
Clinical Respiratory Journal ( IF 1.7 ) Pub Date : 2023-11-10 , DOI: 10.1111/crj.13715
Bo Zhang ₁ , Hua Zhong ₁ , Chunlei Shi ₁ , Zhiqiang Gao ₁ , Runbo Zhong ₁ , Aiqin Gu ₁ , Weimin Wang ₁ , Tianqing Chu ₁ , Liwen Xiong ₁ , Wei Zhang ₁ , Huimin Wang ₁ , Xueyan Zhang ₁ , Baohui Han ₁

Affiliation

Durvalumab is a check-point inhibitor against programmed death ligand-1 (PD-L1), and anlotinib is a new orally administered multitarget tyrosine kinase inhibitor (TKI). Both agents have been approved in China. Preclinical and clinical trials have suggested that antiangiogenic therapy has the potential to alleviate immunosuppression and showed synergetic effect when combined with ICIs. However, it is unclear that whether this combination is effective when initiated as maintenance treatment in ES-SCLC patients.

更新日期：2023-11-10

点击分享查看原文

点击收藏

公开下载

阅读更多本刊最新论文本刊介绍/投稿指南

全部期刊列表>>